Somatostatin analogues for acute bleeding oesophageal varices

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Gøtzsche, Peter C ^a   Hróbjartsson, Asbjørn ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Acute disease; Blood transfusion utilization ; Esophageal and gastric varices *drug therapy; mortality ; Gastrointestinal hemorrhage *drug therapy; mortality ; Hemostatics *therapeutic use ; Octreotide *therapeutic use

Indexed keywords

OCTREOTIDE; PLACEBO; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; VAPREOTIDE;

BALLOON TAMPONADE; BLOOD TRANSFUSION; CLINICAL TRIAL; COCHRANE LIBRARY; DEVICE; ESOPHAGUS VARICES BLEEDING; HEMOSTASIS; HUMAN; LIGATION; MEDLINE; MORTALITY; REVIEW; SCLEROTHERAPY; SURGICAL STAPLING; SURVIVAL; SYSTEMATIC REVIEW;

EID: 55049083759     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000193.pub3     Document Type: Review

References (73)

1. Avgerinos 1997 {published data only} Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: The European ABOVE Study [AASLD abstract]. Hepatology 1996;24(4 Pt 2):191A.
2. Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: the European ABOVE Study [UEGW abstract]. United European Gastroenterology Week, Paris 1996;OP1:0001.
3. * Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997;350:1495- 9. [MEDLINE: 1998049750]
4. Avgerinos A, Nevens F, Raptis S, Fevery J, for the ABOVE study group. Somatostatin for acute oesophageal variceal bleeding [reply]. Lancet 1998;351:911-2.
5. Avgerinos A, Nevens F, Raptis S, Fevery J and the ABOVE Study Group. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in Acute Bleeding Oesophageal Variceal Episodes: the European ABOVE Study [abstract]. Gut 1996;39:A1.
6. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding [comment]. Lancet 1998;351:911.
7. Besson 1995 {published and unpublished data} * Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. New England Journal of Medicine 1995;333:555-60. [MEDLINE: 1995349685]
8. Ingrand P, Rodriguez B, Silvain C, Beauchant M, and a multicenter group. Predictive factors of early variceal bleeding control after emergency sclerotherapy: role of octreotide [abstract]. Journal of Hepatology 1997;26 Suppl 1:P/C02-15.
9. Silvain C, Multricentric Group. A comparison of octreotide combined with endoscopic sclerosis to endoscopic sclerosis alone in the treatment of acute variceal bleeding: a randomized double-blind placebo-controlled trial [EASL abstract]. Journal of Hepatology 1995; 23 Suppl 1:S70.
10. Burroughs 1990 {published data only} * Burroughs AK, McCormick PA, Hughes MD, Sprengers D, D'Heygere F, McIntyre N. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early rebleeding. Gastroenterology 1990;99:1388-95. [MEDLINE: 1991007091]
11. Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N. Randomised double-blind placebo controlled study of somatostatin for control of variceal bleeding [abstract]. Gut 1988; 29(10):A1495.
12. Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N, et al. Randomized, double-blind placebo controlled study of somatostatin for control of variceal bleeding [AASLD abstract]. Hepatology 1988;8:1221.
13. Burroughs 1996 {published data only} Burroughs AK. International Octreotide Varices Study Group. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures [AASLD abstract]. Hepatology 1996; 24:352A.
14. Calès 2001 {published data only} * Calès P, Masliah C, Bernard B, Garnier P-P, Silvain C, Szostak-Talbodec N, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. New England Journal of Medicine 2001;344(1):23-8.
15. Calès P for the French Club for the Study of Pht. Early administration of vapreotide, a new somatostatin analogue, and endoscopic therapy for acute portal hypertensive bleeding in patients with cirrhosis. A randomized trial [abstract 1035]. Hepatology 1999;30(4):419A.
16. Farooqi 2000 {published data only} Farooqi JI, Farooqi RJ, Haq N, Siddiq-Ur-Rehman, Mahmood S. Treatment and outcome of variceal bleeding - a comparison of two methods. Journal of the College of Physicians and Surgeons in Pakistan 2000;10:131-3.
17. Freitas 2000 {published data only} Freitas DS, Sofia C, Pontes JM, Gregorio C, Cabral JP, Andrade P, et al. Octreotide in acute bleeding esophageal varices: a prospective randomized study. Hepatogastroenterology 2000;47(35):1310-4.
18. Gøtzsche 1995 {published and unpublished data} Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin versus placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995;310:1495-8. [MEDLINE: 1995307277]
19. Isaac 1994 {published data only} Isaac J. Pre-sclerotherapy treatment with somatostatin in bleeding oesophageal varices [abstract]. Journal of Gastroenterology and Hepatology 1994;9(3):A35.
20. Morales 2007 {published data only} Morales GF, Pereira Lima JC, Hornos AP, Marques DL, Costa CS, Lima Pereira L, et al. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. Hepatogastroenterology 2007;54(73):195-200.
21. Moretó 1994 {published and unpublished data} MoretóM, Zaballa M, Ruiz-Rebollo L, Calderón A, Ibánez S, Ojembarrena E, et al. Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices [abstract]. Endoscopy 1994;26:407.
22. MoretóM, Zaballa M, Ruiz-Rebollo L, Calderón A, Ibánez S, Ojembarrena E, et al. Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices [abstract]. Gut 1994;35:A178.
23. Pauwels 1994 {published data only} Pauwels A, Florent C, Desaint B, Guivarch P, Van H, Levy V-G. Terlipressine et somatostatine dans le traitement des hémorragies par rupture de varices oesophagiennes [letter]. Gastroenterology and Clinical Biology 1994;18:388-9. [MEDLINE: 1995047127]
24. Shah 1996 {published data only} Shah HA, Mumtaz K, Jafri W, Abid S, Hamid S, Ahmad A, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage. J Ayub Med Coll Abbottabad 2005;17(1):10-4.
25. Shah SHA, Jafri SMW, Ahmed A, Hamid SS, Khan AH. Octreotide use in acute variceal haemorrhage: a prospective randomized study [United European Gastroenterology Week abstract 1215]. Endoscopy 1996;28:S51.
26. Shiha 1996 {published and unpublished data} * Shiha G, Hamid M, El-Said SS, Farag FM, Azzam F, Askalany H. Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial. Mansoura Medical Journal 1996;26: 109-21.
27. Shiha G, Sayed S, Hamid M, Farag M, Azzam F, Assalany H. Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial [UEGW abstract]. Excerpta Medica. 5th United European Gastroenterology Week, Paris 2-6 Nov. 1996: OT51-1066.
28. Signorelli 1996 {published data only} Signorelli S, Negrini F, Paris B, Bonelli M, Girola M. Sclerotherapy with or without somatostatin or octreotide in the treatment of acute variceal haemorrhage: our experience [abstract]. Gastroenterology 1996;110:A1326.
29. Signorelli 1997 {published data only} Signorelli S, Paris B, Negrini F, Bonelli M, Auriemma L. Esophageal varices bleeding: comparison between treatment with sclerotherapy alone vs sclerotherapy plus octreotide [abstract]. Hepatology 1997;26 (4 Pt 2):137A.
30. Souza 2003 {published data only} Souza FC, Arantes V, Cambraia RD, Cangussu LOF, Couto OFM, Teixeira R. Randomized, double blind, trial of octreotide plus endoscopic treatment in controlling gastroesophageal variceal bleeding [abstract]. Journal of Hepatology 2003;38:70.
31. Sung 1995 {published and unpublished data} Sung JJY, Chung SCS, Yung MY, Lai CW, Lau JYW, Lee YT, et al. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation. Lancet 1995;346: 1666-9. [MEDLINE: 1996110602]
32. Valenzuela 1989 {published data only} Valenzuela JE, Schubert T, Fogel MR, Strong RM, Levine J, Mills PR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989;10(6):958-61. [MEDLINE: 1990061178]
33. Villanueva 2001 {published data only} Villanueva C, Ortiz J, Minana J, Soriano G, Sabat M, Boadas J, et al. Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding. Gastroenterology 2001;121:110-7.
34. Zuberi 2000 {published data only} * Zuberi BF, Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. American Journal of Gastroenterology 2000;95(3):768-71.
35. Zuberi BF, Balouch Q. Endoscopic variceal sclerotherapy and octreotide in management of variceal haemorrhage and early re-bleeding [abstract]. Journal of Gastroenterology and Hepatology 1999;14: A15.
36. Brunati 1996 {published data only} * Brunati S, Ceriani R, Curioni R, Brunelli L, Repaci G, Morini L. Sclerotherapy alone vs. sclerotherapy plus terlipressin vs. sclerotherapy plus octreotide in the treatment of acute variceal haemorrhage [abstract]. Hepatology 1996;24(4 Pt 2):207A.
37. Ceriani R, Curioni R, Morini L, Repaci G, Brunati S. Sclerotherapy alone (ES) vs. sclerotherapy plus terlipressin (EST) vs. sclerotherapy plus octrotide (ESO) in the treatment of acute variceal bleeding [abstract]. Gastroenterology 1997;112:A1238.
38. D'Amico 1998 {published data only} D'Amico G, Politi F, Morabito A, D'Antoni A, Guerrera D, Giannuoli G, et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998;28:1206-14.
39. Jenkins 1997 {published data only} Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997;315: 1338-41. [MEDLINE: 1998066478]
40. Primignani 1995 {published data only} Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 1995;21(5):1322-7. [MEDLINE: 1995255802]
41. Ruiz del Arbol 1994 {published data only} Ruiz del Arbol L, Monescillo A, Arocena C, Defarges V, Gisbert J, Vicente M, et al. The pharmacological therapy during the treatment of acute variceal bleeding (A.V.B.) evaluated by variceal pressure-measurement [IASL abstract]. Hepatology 1994;19(4):119I.
42. Shields 1993 {published data only} Shields R, Jenkins SA, Baxter JN, Sutton R, Ellenbogen S. Octreotide in the long term management of portal hypertension: preliminary results of a prospective randomised controlled clinical trial [abstract]. Gastroenterology Supplements. 1993; Vol. 4:A991.
43. Silva 2004 {published data only} Silva G, Quera R, Fluxa F, Sanhueza E, Segovia R, Brahm J, et al. [Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study]. Rev Med Chil 2004;132(3):285-94.
44. UCB trial 1996 {published data only (unpublished sought but not used)} Somatostatin in the control of early rebleeding after sclerotherapy for acute bleeding varices: a multicentre, double-blind randomised placebo-controlled study. Trial MPCE93M0601/1V, sponsored by UCB, Belgium. Unpublished.
45. Albillos 1994 Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. Journal of Hepatology 1994;21(1):88-94. [MEDLINE: 1995052506]
46. Baveno II 1996 De Franchis R, editor. Portal hypertension II. Proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford, UK: Blackwell Science Ltd, 1996.
47. Bornman 1994 Bornman PC, Krige JEJ, Terblanche J. Management of oesophageal varices. Lancet 1994;343(8905):1079-84. [MEDLINE: 1994211066]
48. Chalmers 1990 Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
49. Chan 2004 Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291:2457-65.
50. Cirera 1995 Cirera I, Feu F, Luca A, Garcia-Pagan JC, Fernandez M, Escorsell A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 1995;22(1):106-11. [MEDLINE: 1995324860]
51. D'Amico 2003 D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology 2003;124:1277-91.
52. Escorsell 2001 Escorsell A, Bandi JC, Andreu V, Moitinho E, Garcia-Pagan JC, Bosch J, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120:161-9.
53. Greco 1982 Greco AV, Bianco A, Altomonte L, D'Acquarica L, Ghirlanda G. Effect of somatostatin on lower esophageal sphincter (LES) pressure and serum gastrin in normal and achalasic subjects. Hormone and Metabolic Research 1982;14:26-8. [MEDLINE: 1982140481]
54. Gøtzsche 1989 Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. Danish Medical Bulletin 1989;36:493-5. [MEDLINE: 1990031801]
55. Hanisch 1992 Hanisch E, Doertenbach J, Usadel KH. Somatostatin in acute bleeding oesophageal varices: pharmacology and rationale for use. Drugs 1992;44(Suppl 2):24-35. [MEDLINE: 1993048855]
56. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
57. Hopewell 2004 Hopewell S, Clarke M, Stewart L, Tierney J. Time to publication for results of clinical trials (Cochrane Methodology Review). Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.MR000011.pub2]
58. Kleber 1988 Kleber G, Sauerbruch T, Fisher G, Paumgartner G. Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics. Gut 1988;29:153-6. [MEDLINE: 1988152560]
59. Lamberts 1996 Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. New England Journal of Medicine 1996;334:246-54. [MEDLINE: 1996132562]
60. McCormick 1992 McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992;16(5): 1180-6. [MEDLINE: 1993052079]
61. Møller 1997 Møller S, Brinch K, Henriksen JH, Becker U. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. Journal of Hepatology 1997;26(5):1026-33.
62. Nevens 1994 Nevens F, Sprengers D, Fevery J. The effect of different doses of a bolus injection of somatostatin combined with a slow infusion on transmural oesophageal variceal pressure in patients with cirrhosis. Journal of Hepatology 1994;20(1):27-31. [MEDLINE: 1994260076]
63. Samnegaard 1980 Samnegaard H, Tyden G, Thulin L, Friman L, Uden R. Effect of somatostatin on regional splanchnic blood flows in man: angiographic studies. Acta Chirurgica Scandinavica. Supplementum 1980;500:71-3.
64. Scherer 2004 Scherer RW, Langenberg P. Full publication of results initially presented in abstracts (Cochrane Methodology Review). Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858. MR000005.pub3]
65. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12. [MEDLINE: 1995123716]
66. Sharara 2001 Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. New England Journal of Medicine 2001;345:669-81.
67. Stern 1997 Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997;315:640-5.
68. Williams 1994 Williams SGJ, Westaby D. Management of variceal haemorrhage. BMJ 1994;308:1213-7. [MEDLINE: 1994236061]
69. Gøtzsche 1995 Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin versus placebo in bleeding oesophageal varices: randomised trial andmeta-analysis. BMJ 1995;310:1495-8. [MEDLINE: 1995307277]
70. Gøtzsche 1997 Gøtzsche PC. Somatostatin or octreotide versus placebo in bleeding oesophageal varices. The Cochrane Library 1997, Issue 3.
71. Gøtzsche 1998 Gøtzsche PC. Somatostatin or octreotide versus placebo in bleeding oesophageal varices. The Cochrane Library 1998, Issue 1.
72. Gøtzsche 2002 Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). The Cochrane Library 2002, Issue 1.[Art. No.: CD000193. DOI: 10.1002/14651858.CD000193. pub3]
73. Gøtzsche 2005 Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD000193. DOI: 10.1002/14651858.CD000193.pub2..[Art. No.: CD000193. DOI: 10.1002/14651858. CD000193.pub3]